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Selective adenosine A1 receptor antagonists targeting renal
microcirculation are novel pharmacologic agents that are
currently under development for the treatment of acute
heart failure as well as for chronic heart failure. Despite
several studies showing improvement of renal function
and/or increased diuresis with adenosine A1 antagonists,
particularly in chronic heart failure, these findings were
not confirmed in a large phase III trial in acute heart failure
patients. However, lessons can be learned from these and
other studies, and there might still be a potential role for
the clinical use of adenosine A1 antagonists.
We review the role of adenosine A1 receptors in the
regulation of renal function, and emerging data regarding
the safety and efficacy of A1 adenosine receptor antagonists
based on all available completed and reported clinical trials
using A1 adenosine receptor antagonists. The majority of
trials were done in heart failure patients. However, there
is clear clinical evidence for a role of this new class in
hepatorenal syndrome, hypotension on dialysis, and
radiocontrast media-induced nephropathy.
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Various lines of evidence implicate impaired renal function as
a risk factor in patients with congestive heart failure (CHF).
Conventional diuretics may aggravate renal dysfunction and
can result in neurohumoral activation and activation of the
TGF mechanism in the kidney.1 Impaired kidney function
might not just be a risk factor, but is also currently observed
as having a role—and thus potentially as target—in disease
progression of heart failure patients.1 Evolving new ther-
apeutic strategies that enhance renal function include
administration of B-type natriuretic peptide, adenosine
and vasopressin antagonists, and ultrafiltration methods.
Prospective studies are needed to evaluate whether these new
renal-enhancing strategies will improve patient outcome in
CHF. This review is focused on the up-to-now available
clinical data with A1 adenosine receptor antagonists.
BIOCHEMISTRY AND PHYSIOLOGY OF ADENOSINE
Adenosine is produced from the hydrolysis of adenosine
triphosphate. The actions of adenosine are mediated by
G-protein-coupled receptors that activate second messenger
systems mediating effects in the vascular beds as well as other
structures (for example, macula densa and renal tubular cells)
of the kidney, brain, and heart. Four subtypes of adenosine
receptors have been identified: A1, A2a, A2b, and A3. The
receptors A1 and A3 are coupled to the pertussis toxin-
sensitive Gi proteins and inhibit adenylyl cyclase, whereas
the A2a and A2b receptors activate Gs proteins to stimulate
adenylyl cyclase and cyclic adenosine monophosphate
production.2–4
In the heart and many other vascular beds, adenosine
functions primarily as a vasodilator through the activation of
A2a receptors,2,3 but there is also evidence for functional
cardiac A1 adenosine receptors.2–4 In the kidney, activation of
adenosine A1 receptors in the afferent arteriole results in
vasoconstriction that reduces the glomerular filtration rate
(GFR) and renal blood flow and mediates TGF. This net
vasoconstriction occurs despite the presence of A2a receptors
in the efferent arteriole. In the kidney, A1 adenosine receptors
have been localized in the afferent arteriole, glomerulus,
proximal tubule, and collecting ducts, whereas A2a adeno-
sine receptors are located primarily in efferent arterioles.
Infusion of selective A1 adenosine antagonists into the renal
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vasculature causes diuresis and natriuresis, indicating that
these receptors also mediate sodium and water reabsorption.5
The ability of A1 adenosine receptor blockers to preserve
GFR by inhibiting TGF further promotes salt and water
excretion by the kidney.5
The ability of specific adenosine A1 receptor antagonists
to induce diuresis and natriuresis while not compromising
GFR and also renal blood flow has thus become an attractive
therapeutic option for the treatment of fluid retention
disorders, especially in (1) severe kidney disease, (2) liver
cirrhosis with ascites, and (3) in acute heart failure (AHF)
and chronic heart failure. We review below the available
information on clinical trials of A1 adenosine antagonists
in these indications. Key information on the characteristics of
different compounds is summarized in Table 1, whereas the
key trial information is summarized in Table 2.
ALTERING KIDNEY FUNCTION IN ADVANCED LIVER
CIRRHOSIS
Liver cirrhosis is associated with a progressive deterioration
of kidney function, starting with diuretic-resistant ascites in
liver cirrhosis followed by hepatorenal syndrome type 1 and
2. Although urgently needed, there is, however, no estab-
lished pharmacological approach for the treatment of these
Table 1 | Direct comparison of Ki values from different A1
adenosine receptor blockers currently in clinical
development (data obtained from Solvay Pharmaceuticals,
Hannover, Germany)
Ki (nM) SLV320
BG9928
(Adentri)
KW3902
(Rolofylline)
A1-receptor, human 1 7.4 5
A2A-receptor, human 398 6600 158
A2B-receptor, human 3981 90 316
A3-receptor, human 200 22,000 2000
A2A/A1 398 892 31.6
Synonyms are given in booklets; SLV320 has no synonym so far.
Table 2 | Summary of all phase II and III clinical studies performed so far using A1 adenosine receptor antagonists
Study title/references Study design Study population Findings Compound
Natriuretic effect of an
adenosine-1 receptor
antagonist in cirrhotic
patients with ascites8
Open-labeled pilot
study
12 patients with liver
cirrhosis and ascites
refractory to loop
diuretics
Urine sodium excretion and urine flow rate
increased after FK352. Plasma cAMP and
angiotensin II levels and plasma renin activity
also increased. No change was detected in
renal blood flow, glomerular filtration rate,
and cardiac output
FK352
Adenosine A1 receptor
antagonist improves
intradialytic hypotension9
Double-blind,
placebo-controlled
30 patients on
hemodialysis
FK352 significantly improved intradialytic
hypotension. The frequency of discontinuation of
dialysis was significantly reduced by FK352. No
apparent side effects were observed
FK352
The effects of KW-3902, an
adenosine A1-receptor
antagonist, on diuresis and
renal function in patients with
acute decompensated heart
failure and renal impairment
or diuretic resistance10
Double-blind,
placebo-controlled
146 ADHF patients
with renal
impairment
+
35 diuretic-resistant
ADHF patients
In ADHF protocol, 146 patients with volume
overload and an eGFR of 20 to 80ml/min were
randomized to placebo or 1 of 4 doses of KW-
3902 (rolofylline) infused over 2 h daily for up to
3 days. On day 1, KW-3902 monotherapy
increased urine output during the first 6 h
compared with placebo. On day 2, serum
creatinine decreased in all KW-3902 groups and
increased with placebo. By day 4, or day of
discharge if earlier, intravenous furosemide
administration tended to be lower in the KW-3902
groups compared with placebo. In diuretic-
resistant protocol, 35 patients with an average
eGFR of 34ml/min were randomized to a single
infusion of placebo or KW-3902. Compared with
placebo, KW-3902 increased hourly urine volume
and eGFR with peak effects occurring at 2 to 3 h
and at 24 h, respectively. Adverse events were not
different between placebo and KW-3902
KW-3902
Cardio-renal effects of the A1
adenosine receptor antagonist
SLV320 in patients with heart
failure13
Double-blind,
placebo-controlled
111 chronic
HF patients
Heart rate, blood pressure, PCWP, MPAP, RAP,
SVR, and CO were not altered by any dose of a
single i.v. SLV320 dose. Changes from baseline
cystatin C plasma concentrations decreased after
10mg SLV320, whereas furosemide treatment
resulted in a significant increase in cystatin
C versus baseline. SLV320 increased significantly
sodium excretion and diuresis when compared
with placebo during 0–6 h collection period after
dosing. SLV320 was well tolerated, and no serious
adverse events were observed
SLV320
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Table 2 | Continued
Study title/references Study design Study population Findings Compound
BG9719 (CVT-124), an A1
adenosine receptor antagonist,
protects against the decline in
renal function observed with
diuretic therapy12
Double-blind,
ascending-dose,
crossover study
63 chronic
HF patients
BG9719 alone caused an increase in urine output
and sodium excretion. Although administration of
furosemide alone caused a large diuresis, addition
of BG9719 to furosemide increased diuresis.
BG9719 alone improved GFR at the two lower
dosages. Furosemide alone caused a decline in
GFR. However, when BG9719 was added to
furosemide, creatinine clearance remained at
baseline at the two lower doses. BG9719 was
well tolerated
BG9719
(CVT-124)
Effects of BG9719 (CVT-124),
an A1-adenosine receptor
antagonist, and furosemide
on glomerular filtration rate
and natriuresis in patients with
congestive heart failure14
Randomized,
double-blind,
placebo-controlled,
parallel design
12 chronic
HF patients
GFR was 84.6ml/min per 1.73m2 after receiving
placebo, 82.6 after BG9719 administration, and
decreased to 63.6 after furosemide. Total renal
plasma flow was similar in all groups. Sodium
excretion increased after BG9719 and furosemide.
Diuresis was more pronounced in the furosemide
group, but also increased after BG9719
BG9719
The effect of KW-3902, an
adenosine A1 receptor
antagonist, on renal function
and renal plasma flow in
ambulatory patients with heart
failure and renal impairment15
Double-blind,
placebo-controlled,
two-way crossover
study
32 chronic
HF patients
GFR increased by 32% and renal plasma flow
increased by 48%. Furthermore, subjects who
initially received KW-3902 returned for the
crossover phase (median 6 days) with a persistent
10ml/min increase in GFR more than their
previous baseline
KW-3902
Effects of multiple oral doses
of an A1 adenosine antagonist,
BG9928, in patients with heart
failure17
Randomized,
double-blind,
placebo-controlled
study
50 chronic
HF patients
BG9928 increased sodium excretion compared
with placebo, and natriuresis was maintained over
10 days with little kaliuresis. GFR was unchanged
over 10 days. Patients who received BG9928 had a
reduction in body weight compared with placebo.
At the end of study, BG9928 was well tolerated
BG9928
The PROTECT pilot study: a
randomized, placebo-
controlled, dose-finding study
of the adenosine A1 receptor
antagonist rolofylline in patients
with acute heart failure and
renal impairment19
Randomized,
double-blind,
placebo-controlled,
parallel design
301 ADHF patients
with renal
impairment
There was a trend of rolofylline toward greater
proportions of patients with marked or
moderately improved dyspnea and fewer patients
with worsening heart failure or renal function.
The trend was driven by improvement in dyspnea.
Serum creatinine increased in patients receiving
placebo and remained stable or tended to
decrease in those receiving rolofylline. On day 14
the absolute differences between placebo and
rolofylline for change in creatinine increased with
increasing rolofylline dose. Treatment with 30mg,
the dose selected for the pivotal trials, was
associated with a trend toward reduced 60-day
mortality or readmission for cardiovascular or
renal cause
KW-3902
The PROTECT study20 Randomized,
double-blind,
placebo-controlled,
parallel design
2033 ADHF patients
with renal
impairment
Dyspnea improved at both 24 and 48 h after
dosing in 51.2% in the rolofylline group and 44.5%
in the placebo group. Death or cardiovascular
or renal hospitalization occurred in 30.7% of
rolofylline patients (25.7% were hospitalized
and 8.9% died) and 31.9% of placebo patients
(25.6% were hospitalized and 9.5% died). Serum
creatinine increase of X0.3mg/dl through day 7
confirmed at day 14 was observed in 12.3% in the
rolofylline group and in 10.6% in the placebo
group. Initiation of hemofiltration was needed in
0.4% of all patients in the rolofylline group and in
0.9% in the placebo group. More patients on
rolofylline experienced nervous system disorders,
with 11 patients (0.8%) experiencing seizure and
16 patients (1.2%) experiencing stroke on
rolofylline, with no patients experiencing seizure
and 3 patients (0.5%) experiencing stroke in
placebo
KW-3902
Abbreviations: ADHF, acute decompensated heart failure; cAMP, cyclic adenosine monophosphate; CO, cardiac output; eGFR, estimated glomerular filtration rate; HF, heart
failure; MPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; SVR, systematic vascular resistance.
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conditions.6 Animal studies suggest that a resetting of TGF
may contribute to the pathophysiology of kidney impairment
in liver cirrhosis.7 This hypothesis was even tested clinically
some years ago in a small phase II study using FK352, a novel
pyrazolopyridine derivative that has been characterized
in vitro as a highly selective A1 adenosine receptor
antagonist.4 This study was a phase II open-labeled study,
designed primarily to assess the efficacy and safety of FK352.
A dose escalation was built into the study to identify any dose
response. p-Aminohippuric acid and inulin clearance, urine
flow rate, sodium and potassium excretion, and free water
clearance were measured for 2 h before and after FK352
administration. Cardiac output, systemic vascular resistance,
plasma angiotensin II level, plasma renin activity, noradrena-
line, adrenaline, and adenosine 30-50-cyclic monophosphate
levels were also measured before and after FK352.8 Urine
sodium excretion and urine flow rate increased after FK352
substantially. Plasma cyclic adenosine monophosphate and
angiotensin II levels and plasma renin activity also increased.
No change was detected in any other parameters.8 These data
indicate that an A1 adenosine receptor antagonist may induce
water and salt excretion in patients with liver cirrhosis without
compromising renal blood flow and GFR. This may offer a new
horizon in the so far disappointing attempts to treat kidney
dysfunction in liver cirrhosis.6 Clearly, larger studies, including
studies in patients with even more advanced disease stages, are
needed before coming to final conclusions.
INFLUENCING INTRADIALYTIC HYPOTENSION IN
END-STAGE RENAL DISEASE PATIENTS
Sudden hypotension during dialysis (intradialytic hypoten-
sion) is a frequent complication of hemodialysis. This may
contribute to cardiovascular events and high mortality and is
limiting both qualities of life of the patients on hemodialysis
and the quality of dialysis itself. This condition is particularly
frequent in patients with diabetic nephropathy and occurs
usually 1 h after initiation of dialysis. There were indications
that an increase in adenosine generation during hemodialysis
may cause vasodilation and a decrease in cardiac output,
which results in systemic hypotension. The effects of an
A1 antagonist, FK352, injection in 30 chronic hemodialysis
patients with frequent intradialytic hypotension were investi-
gated in a prospective, multicenter, double-blind placebo-
controlled study for 4 weeks.9 Intradialytic hypotension was
defined as systolic blood pressure of o110 mm Hg,
with its drop of 430 mm Hg from the predialysis level.
The efficacy of FK352 was primarily assessed by the reduction
rate of dialysis hypotension between the FK352 and placebo
groups. Incidence of emergency treatments caused by
hypotension was evaluated. FK352 significantly improved
intradialytic hypotension. The frequency of discontinuation
of dialysis was also significantly reduced by FK352. No
apparent side effects were observed from treatment with
FK352.9 Taken together, patients with frequent hypotension
on dialysis may benefit from a prophylactic treatment with an
A1 adenosine receptor antagonist.
TARGETING DIURETIC RESISTANCE
Resistance to loop diuretics may occur in patients with heart
failure and also in different forms of advanced renal disease
(secondary renal diseases such as later stages of diabetic
nephropathy and also primary renal diseases such as focal
segmental glomerulonephritis). When conservative app-
roaches including sequential nephron blockade do not work,
costly and invasive techniques such as hemofiltration may
became the only way to improve the fluid status of the
patient. It was suggested that an activated TGF might be a key
pathophysiological cause of resistance to diuretics. This
hypothesis was tested in heart failure patients resistant to
diuretics in a randomized, double-blind, placebo-controlled,
dose-escalation study.6 Resistance to diuretics was defined
clinically by the blinded physician. The patients had to have
reached the point in which a further increase in diuretic
therapy was unlikely to be effective or would worsen renal
function and in which the investigator was considering more
aggressive management of fluid overload, including the use of
further intravenous (i.v.) vasoactive medications, mechanical
circulatory support, ultrafiltration, or dialysis. Examples of
diuretic refractoriness included: the combination of i.v.
furosemide plus oral metolazone given X1 times (nephron
blockade) per day, or an infusion of furosemide at
420 mg/h that does not yield any significant increase in
urine output or reduction in edema, weight, or fluid volume
status.10 A total of 35 patients with an average creatinine
clearance of 34 ml/min were randomized to a single infusion
of placebo, 10, 30, or 60 mg of KW-3902. Compared with
placebo, KW-3902 increased hourly urine volume and
estimated GFR with peak effects occurring at 2 to 3 h and
at 24 h, respectively.10 This indicates that A1 adenosine
receptor antagonists may overcome resistance to diuretics in
heart failure. This needs to be confirmed in larger studies
including other conditions also of resistance to treatment
with diuretics.
TREATMENT OF CHRONIC HEART FAILURE
Baseline kidney function, measured most often as estimated
GFR, is associated with a poor outcome in heart failure
patients. Moreover, worsening of GFR (mainly characterized
as change of baseline estimated GFR versus day 2) is
frequently observed in patients with AHF syndromes and
adds additional mortality risk. On the other hand, improve-
ment in estimated GFR is associated with a somewhat better
outcome even in terms of mortality.1,11 Thus, it was proposed
that therapeutic strategies to improve kidney function in
heart failure patients may translate in symptomatic and even
mortality benefits in patient with both chronic heart failure
and AHF. This hypothesis was first investigated in patients
with chronic stable heart failure. The pioneering work was
carried out by Gottlieb et al.12 They performed a randomized,
double-blind, ascending-dose, crossover study evaluating
three doses of BG9719 in 63 patients with CHF. Patients
received placebo or 1 of 3 doses of BG9719 on one day and
the same medication plus furosemide on a separate day.
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Renal function and electrolyte and water excretion were
assessed. BG9719 alone caused an increase in urine output
and sodium excretion. Although administration of furose-
mide alone caused a large diuresis, addition of BG9719 to
furosemide increased diuresis. BG9719 alone improved GFR
at the two lower doses. Furosemide alone caused a decline in
GFR. However, when BG9719 was added to furosemide,
creatinine clearance remained at baseline at the two lower
doses and diuresis was even further improved. The direct
opposite effects of furosemide and an A1 adenosine receptor
antagonist (SLV320) on kidney function in terms of GFR
were later confirmed using cystatin C as biomarker for
GFR.13 This study furthermore showed that an A1 adenosine
receptor antagonist has no immediate cardiac effects
(no effects on any of the hemodynamic parameters: heart
rate, blood pressure, pulmonary wedge pressure, mean
pulmonary arterial pressure, systemic vascular resistance,
right atrial pressure, and cardiac output). However, it is
important to note that furosemide led in this study to a
significant increase in total peripheral resistance. This was
not observed with any of the SLV320 dosages.13
The finding that an A1 adenosine receptor antagonist
improves GFR while simultaneously promoting natriuresis
and diuresis with minor effects on potassium excretion was
consistent in several studies in chronic heart failure
patients.12–16 It is noteworthy that in chronic heart failure
patients,15 the effect of a single injection of the A1 adenosine
receptor antagonist seems to persist for several days15—much
longer as the half-life time of the A1 adenosine receptor
antagonist in the plasma of these patients, suggesting long-
lasting, yet on a molecular basis not understood, effects of an
A1 adenosine receptor antagonist on the TGF.
Effects of an orally available A1 adenosine receptor
antagonist were analyzed in a randomized, double-blind,
placebo-controlled study in patients with heart failure and
systolic dysfunction who were receiving standard therapy.
Patients were randomized to receive BG9928 (3, 15, 75, or
225 mg) or placebo orally for 10 days. This study showed that
oral BG9928 over the dose range of 3 to 225 mg/day
produced significant increases in sodium excretion in
patients with stable heart failure without causing kaliuresis
or reducing renal function.17 All studies performed so far
in stable heart failure patients9–14 consistently show that A1
adenosine receptor antagonists increase sodium excretion
and dieresis without compromising renal blood flow and
GFR. Loop diuretic-induced compromising of GFR seems to
be abolished by A1 adenosine receptor antagonists.
TREATMENT OF AHF
It was assumed that the claimed mechanism of action of
A1 adenosine receptor blockade in chronic heart failure
(A1 adenosine receptor blockade may abolish the loop
diuretic-induced disturbance of renal microcirculation and
hence improve kidney function) also holds in acutely
decompensated heart failure patients. Two clinical phase II
studies18,19 supported this hypothesis. However, preclinical
evidence was missing simply because of lack of adequate
animal models for AHF. The PROTECT pilot study,
however, showed very promising data, indicating that this
class of drugs might improve mortality, symptoms of AHF,
and kidney function with an acceptable safety profile.19 The
main driver for success in this study was improvement in
dyspnea.19
The PROTECT pilot study was primarily designed to
develop the primary end point for the phase III registration
trial: the PROTECT study. The PROTECT data were
presented at the European Society of Cardiology meeting
2009 in Barcelona, Spain. The abstract and the presentation
were made available on the web site of the European Society
of Cardiology, 2 September 2009.20 PROTECT was a multi-
center, randomized, double-blind, placebo-controlled study
in patients hospitalized for AHF syndromes manifest by
dyspnea at rest and signs of volume overload requiring i.v.
loop diuretic therapy. Patients were anticipated to require
ongoing i.v. furosemide X40 mg/day for at least 24 h after
enrollment and had to have impaired renal function
(estimated creatinine clearance 20–80 ml/min). In addition,
patients were required to have a brain natriuretic peptide
level of X500 pg/ml or N-terminal prohormone brain
natriuretic peptide level of X2000 pg/ml. Key exclusions
were ongoing or planned i.v. vasoactive therapy (except for
nitrates), mechanical/circulatory support, ultrafiltration,
dialysis, acute coronary syndromes, severe cardiac valve
stenosis, or high risk for seizures. Randomization was to
occur within 24 h and rolofylline 30 mg/day i.v., or matching
placebo was infused shortly thereafter for 4 h/day for up to
3 days. The primary end point was a three-category ordered
outcome of treatment success, lack of change, or treatment
failure, assessed through day 7 or discharge. Treatment
success was defined as moderate-to-marked improvement in
dyspnea at both 24 and 48 h after randomization in the
absence of treatment failure. Treatment failure included any
of the following: death or readmission for heart failure
through day 7, worsening symptoms and/or signs of heart
failure after day 2 through 7, or discharge with the need for
rescue therapy and persistent renal impairment (serum
creatinine increase of X0.3 mg/dl through day 7 confirmed
at day 14, or initiation of hemofiltration or dialysis through
day 7). Secondary end points included time to death or
rehospitalization for cardiovascular or renal causes through
day 60 and the proportion of patients with persistent renal
impairment (serum creatinine increase of X0.3 mg/dl from
randomization to day 7, confirmed at day 14, initiation of
hemofiltration or dialysis, or death up to day 7).
A total of 2033 patients were randomized to rolofylline
(n¼ 1356) and placebo (n¼ 677). For the primary end point,
rolofylline was associated with more successes than placebo,
but also more failure (odds ratio versus placebo 0.92, 95%
confidence interval 0.78–1.09, P¼ 0.348). It is noteworthy
that moderate-to-marked improvement in dyspnea at both
24 and 48 h was observed in 51.2% in the rolofylline group
and 44.5% in the placebo group. The secondary composite
442 Kidney International (2010) 78, 438–445
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end point of death or cardiovascular or renal hospitalization
occurred in 30.7% of rolofylline patients (25.7% were
hospitalized and 8.9% died) and 31.9% of placebo patients
(25.6% were hospitalized and 9.5% died), yielding a time-to-
first-event hazard ratio of 0.98 (95% confidence interval
0.83–1.17, P¼ 0.86).
Serum creatinine increase X0.3 mg/dl through day 7
confirmed at day 14 was observed in 12.3% in the rolofylline
group and in 10.6% in the placebo group. Initiation of
hemofiltration was needed in 0.4% of all patients in the
rolofylline group and in 0.9% in the placebo group. More
patients on rolofylline experienced nervous system disorders,
with 11 patients (0.8%) experiencing seizure and 16 patients
(1.2%) experiencing stroke on rolofylline, with no patients
experiencing seizure and 3 patients (0.5%) experiencing
stroke in placebo.20 In conclusion, PROTECT showed
that rolofylline treatment was almost neutral with respect
to mortality/hospitalization. The treatment also showed an
improvement in dyspnea, but seemed to worsen kidney
function. It is noteworthy that the rolofylline effect on
dyspnea was sustainable when compared with brain na-
triuretic peptide/nesiritide effects. Nesiritide was approved by
the regulatory authorities for treatment of AHF and showed
only a relatively short-term improvement of clinical symp-
toms.21 Rolofylline treatment seems to have a much longer
effect on dyspnea.20 Rolofylline treatment was associated with
an increased number of seizures (a seizure risk was
anticipated, as A1 adenosine receptors have a pivotal role
in the brain)3 and a trend for an increased number of strokes.
The finding of even a moderate worsening of kidney function
is in contradiction to the underlying hypothesis of the
development programs of A1 adenosine receptor blockers in
AHF. Currently, three different compounds, SLV320,4,13
Rolofylline,19,20 and Adentri,22 are in development for this
indication. Adentri is currently in a phase IIb trial versus
placebo in addition to standard of care, called the TRIDENT-
1 (TReatment with Intravenous BG992822 for patients with
acutely Decompensated heart failure and reNal insufficiency
Trial) study.18
Blockade of the TGF by A1 adenosine receptor antagonists
(in volume overloaded, AHF patients with concomitant renal
impairment) was expected to improve renal function.2,3
However, a substantial proportion of these patients might
also suffer from acute renal failure because of hypotension-
induced acute tubular necrosis. Data in A1 adenosine
knockout mice suggest that blocking the A1 receptor in
these patients might even further harm kidney function by
promoting reperfusion injury.23 Taken together, there might
be two independent mechanisms with respect to the A1
adenosine receptor acting in AHF on the kidney: the TGF
mechanism and the A1 adenosine receptor-mediated effects
on reperfusion injury after hypotension-induced acute
tubular necrosis. The first is protective for the kidney; the
latter will rather be harmful for the kidney function. The net
effect of both pathways (A1 adenosine receptor-mediated
blockade of the TGF and A1 adenosine receptor blockade-
induced aggravation of tubular damage) might explain the
overall neutral PROTECT study results. This might also
explain the discrepancy between findings in CHF and AHF
patients. The effect of A1 adenosine receptor blockers on
hypotension-induced reperfusion injury of the kidneys might
be much less important in CHF patients, simply because they
are stable with respect to blood pressure.
It must be kept in mind that kidney function was assessed
in the PROTECT trial with an exploratory renal end point
invented in the PROTECT pilot study. This renal end point
was never used before in any clinical study.24–28 Therefore,
the renal end point of the PROTECT study was at high risk
for failure and its clinical implications (predictive value for a
morbidity/mortality end point of a phase III trial) are
unknown and remain to be investigated.
A post hoc analysis was conducted to identify the dose and
time points after drug administration with the highest trend
of benefit. Other time points after intervention or other
dosages did not show any clear signal. There was no clear
dose dependency and also no clear time dependency of the
renal effects observed.19 Thus, the PROTECT investigators
took a very high risk for failure of the end point for their
phase III study based on the way of how they used the
PROTECT pilot trial to define this end point. In addition, the
major disadvantage of such an invented renal end point is
indeed that the clinical implications remain uncertain.24–28
The trend toward increase of strokes in the rolofylline group
of the PROTECT trial raises the question of an off-target
effect. Careful head-to-head comparison with respect to
risk factors for stroke of all A1 adenosine receptor
antagonists3,13,19,20,22) currently under development is urgently
needed. In any case, a genetic disruptor of the A1 adenosine
receptor gene in mice (A1 adenosine receptor knockout mice)
is not known to increase the risk for strokes in these animals.
Treatment with theophylline, a non-selective adenosine
receptor antagonist, is also not associated with an increased
risk for strokes, supporting an off-target effect of rolofylline. In
contrast, non-selective adenosine receptor blockade was even
considered for the treatment of stroke.29
Receptor selectivity toward the four different adenosine
receptors might also be an efficacy and safety factor for
potential cardiorenal indications. Blocking the A1 adenosine
receptor increases blood flow in the vas afferens of the
glomerulum, whereas blockade of the A2a receptor in the vas
efferens decreases blood flow in the glomerulus.2,3 Thus, the
A1/A2a ratio and the A1 adenosine receptor affinity are most
likely efficacy parameters (see Table 1). However, this needs
to be shown in adequate studies (for example, analyzing
the effects of A1 adenosine receptor antagonists in vas
afferents and efferens of isolated glomeruli). The cardio-
vascular research unit of Solvay Pharmaceuticals (Hannover,
Germany) performed a head–to-head comparison of A1
adenosine receptor antagonists in clinical development
(Table 1) showing differences in the A2a/A1 ratio of the
different compounds. Similar concepts were shown to be of
clinical impact for b-receptor blockers in heart failure.30,31
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OTHER INDICATIONS FOR A1 ADENOSINE RECEPTOR
ANTAGONISTS?
A genetic as well as pharmacological blockade of the A1
adenosine receptor has been shown to prevent radiocontrast
media-induced nephropathy in an animal model.32 There are
even supportive clinical data available using the non-selective
adenosine receptor antagonist theophylline.33–35 Radiocon-
trast media-induced nephropathy in high-risk patients for
this disease (for example, diabetics with pre-existing renal
impairment) is associated with a remarkable high morbidity
and mortality.36
There is evidence that the A1 adenosine receptor
contributes to fibrotic remodeling of the heart.4,37 Blocking
the A1 adenosine receptor might be a therapeutic approach
in the treatment of uremic heart disease.4
A very recent study suggests that targeting A1 adenosine
receptors may be effective in the prevention of alcohol-
induced fatty liver.38 Considering the already shown potential
clinical effects8 of A1 adenosine receptor antagonists on
kidney function in advanced stages of alcoholic liver disease
might further support clinical work in this field.
Adenosine produces bronchoconstriction in allergic rab-
bits, primates, and humans by activating A1 adenosine
receptors. In line with this finding are data indicating that
A1 adenosine receptor blocker might be therapeutically
useful in experimental asthma models.39 A1 adenosine
receptor blockers with a PD4 inhibitory property such as
SLV3203,4 might be of particular interest in this indication.
CONCLUSIONS
A1 adenosine receptor antagonists are currently in clinical
development in AHF and chronic heart failure. Recent data
from the PROTECT trial may suggest that the pathophysiol-
ogy of the adenosine system is different in AHF and chronic
heart failure. In the cardiovascular clinical field, treatment
targets of A1 adenosine receptor antagonists remain AHF and
chronic heart failure, particularly in situations in which
renal impairment and/or resistance to diuretics is highly
relevant. Other indications may be liver cirrhosis and
sudden hypotension on dialysis. Preclinical data clearly
support clinical work in patients with radiocontrast media-
induced nephropathy, cardiac fibrosis, fatty liver disease,
and asthma.
Considering the disappointing results from the first phase
III trial using A1 adenosine receptor antagonist (PROTECT
trial), the common characteristics and even more impor-
tantly the differences in the available A1 adenosine receptor
antagonists when it comes to their effects and side effects
need detailed study. Differences in receptor selectivity, brain
penetration, and pharmacokinetics of the A1 adenosine
receptor antagonists currently in development might be key
factors for efficacy and safety of this promising new class of
cardiovascular compounds. A detailed understanding of the
underlying pathophysiology of the adenosine system is a
must in any clinical development plan and was probably
missing in AHF.
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